10
NEWS
Diagnoses
doubles
New data shows a stark increase in
the number of people living with a
diabetes diagnosis. Analysis from
Diabetes UK shows that over 4.1
million adults live with a diabetes
diagnosis in the UK, with 203,499
adults in Wales living with the
condition, 90 per cent of those with
Type 2.
The charity's new figures suggest
that a further 850,000 living with
Type 2 diabetes across the UK and
an additional 61,488 people in Wales
are yet to be diagnosed. Data from
the National Diabetes Audit in 2020
suggests that, including those under
17, the figure is even higher, with
209,015 people with a Type 1 or Type
2 diabetes diagnosis.
Cases of Type 2 diabetes
diagnoses have doubled in the last 15
years. But research has consistently
shown that for some people,
combined lifestyle interventions
- including diet, physical activity
and sustained weight loss - can be
effective in reducing the risk of Type
2 diabetes by about 50%. NHS Wales
estimates that rates will increase to
11.5% of the population by 2030.
Steering
group experts
Diabetes UK has appointed four
new diabetes experts to lead the
Diabetes Research Steering Groups
(DRSGs). DRSGs bring together
people living with diabetes,
healthcare professionals, and
diabetes researchers and help guide
diabetes research in the UK to have
the biggest impact in the areas that
matter most to people living with the
condition. To find out more about
the new appointees and the steering
groups, CLICK HERE.
FDA clears
Unity
Bigfoot Biomedical has received
FDA 510(k) clearance for its Bigfoot
Unity diabetes management system.
The Bigfoot Unity system features
connected smartpen caps designed
to recommend insulin doses for
people with diabetes using multiple
daily injection (MDI) therapy in
the US. The smartpen caps offer
on-demand insulin dose decision
support to minimise guesswork. The
device is compatible with all major
US brands of rapid- and long-acting
disposable insulin pens, including
made by Eli Lilly, Novo Nordisk
and Sanofi.
New Board members
JDRF has welcomed three new members to the charity's UK Board
of Directors Jared Chebib, Wilson Leech and Per Lundin have begun
their first three-year terms at the charity, which funds research to
eradicate Type 1 diabetes and its effects for everyone in the UK.All
three Directors have personal experience of life with type 1 diabetes.
Wilson and Per have the condition themselves, while Jared is the
father of a child who lives with Type 1. At the same time as welcoming
the new Directors, JDRF said goodbye to Karen Loumansky, who is
stepping down as a Board Director after two terms totalling six years.
Chebib joins the Board as Treasurer-elect, He has worked in
financial services for more than 25 years. His daughter's Type 1
diagnosis gave him a deep appreciation for the importance of JDRF
and the research that it supports.
Leech is an experienced Chief Executive and Chief Financial
Officer who has worked in financial services throughout his career.
He was diagnosed with type 1 diabetes aged 16 and previously served
on the Board of JDRF in the US. He is most interested in technological
advancements to help manage Type 1 diabetes.
Lundin has many years' medical research experience, having
completed a PhD in Medical Science at the Karolinska Institutet
in Sweden. He is also the co-founder and Chief Operating Officer
of biotechnology company Evox Therapeutics, which develops
drugs for rare diseases. He was diagnosed with Type 1 as a young
adult and is passionate about contributing to JDRF's mission to end
Type 1 diabetes.
GlucoContro
Ascensia Diabetes Care has
launched a diabetes management
and analytics platform for
people using its Contour blood
glucose monitoring portfolio. The
browser-based GlucoContro.
online platform allows people
with diabetes to access their
diabetes data online and share it
with their healthcare providers
and caregivers through dedicated
web apps. The platform is
available in the UK, Ireland, Spain,
KSA, Slovenia, Italy and Poland,
with further plans to launch in
other markets throughout the
year where the Contour Diabetes
app is available.